STOCK TITAN
  1. Home
  2. News
  3. BVAXF

BioVaxys Technology Corp - BVAXF STOCK NEWS

Welcome to our dedicated news page for BioVaxys Technology (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on BioVaxys Technology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioVaxys Technology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioVaxys Technology's position in the market.

News
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
Rhea-AI Summary
BioVaxys Technology Corp. is providing a bi-weekly update on the status of the management cease trade order (MCTO) granted by the Ontario Securities Commission. The delay in filing required financial statements is due to the auditor needing more time to complete the audit. The MCTO extension has been granted until May 13, 2024, to allow for the completion of the audit related to the recent acquisition of assets from IMV Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY
Rhea-AI Summary
BioVaxys Technology Corp. and SpayVac-for-Wildlife, Inc. announce a partnership to field test immuno-contraceptive vaccines in farmed rainbow trout. The technology aims to manage challenges in aquaculture industry and prevent breeding with wild fish. Initial trials show promising results, with plans to expand to other animal species.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
none
-
News
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE
Rhea-AI Summary
BioVaxys Technology Corp. receives a Notice of Allowance from the USPTO for a Patent on inducing an antibody immune response using low dose volume delivery of a B-cell epitope formulated with DPX™. The company's proprietary lipid-based delivery platform DPX™ shows promise for cancer immunotherapeutics and therapeutic vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
clinical trial
News
BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order
Rhea-AI Summary
BioVaxys Technology Corp. announced that the Ontario Securities Commission granted a management cease trade order due to delayed financial filings. The delay was caused by additional information needed for audits and recent acquisitions. The Company expects to file the Required Reports within 30 days of the original deadline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.33%
Tags
none
-
News
BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications
Rhea-AI Summary
BioVaxys Technology Corp. receives a Notice of Allowance from the Japanese Patent Office for a Patent related to inducing an antibody immune response using a low dose volume delivery of a B-cell epitope formulated with DPX™. The DPX™ platform attracts antigen presenting cells to the injection site, enhancing immune response. BioVaxys also files an international patent application for methods of formulating DPX™ compositions with lipid-based and polynucleotide adjuvants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
none
-
News
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.
Rhea-AI Summary
BioVaxys Technology Corp. completes the acquisition of IMV Inc.'s assets, expanding its portfolio in oncology, infectious disease, allergy desensitization, and autoimmune diseases. The acquisition includes clinical-stage programs like Maveropepimut-S, with plans for organic growth through licensing and partnership opportunities. The Company aims to leverage the DPX™ and HapTenix© platforms for targeted immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
acquisition
News
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.
Rhea-AI Summary
BioVaxys Technology Corp. acquires IMV's extensive technology portfolio through an Asset Purchase Agreement, including the DPX™ immune educating platform. The transaction involves upfront cash payment, milestone payments, royalties, and shares of BioVaxys common stock. BioVaxys gains access to DPX™ antigen delivery platform for cancer immunotherapies, specifically maveropepimut-S. The acquisition includes patents, patent applications, international filings, trademarks, and intellectual property. BioVaxys aims to expand its pipeline in oncology, infectious diseases, and immunological fields, positioning itself as a key player in cancer immunotherapy and other verticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.17%
Tags
acquisition
-
News
BIOVAXYS ANNOUNCES COMPLETION OF FINAL TRANCHE OF PRIVATE PLACEMENT
Rhea-AI Summary
BioVaxys Technology Corp. completes a non-brokered private placement, raising $501,500 through 16,716,666 Units at $0.03 per Unit. Each Unit includes a Common Share and a Warrant. The Company plans to utilize the proceeds for working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
BIOVAXYS ANNOUNCES COMPLETION OF FIRST TRANCHE OF PRIVATE PLACEMENT
Rhea-AI Summary
BioVaxys Technology Corp. completes the first tranche of a non-brokered private placement, raising $1,103,500 through the issuance of 36,783,334 Units at $0.03 per Unit. Each Unit includes one Common Share and one Warrant exercisable at $0.05. The Company plans to use the proceeds for working capital, with the second tranche expected to close by February 9th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
BIOVAXYS ANNOUNCES COMPLETION OF FIRST TRANCHE OF PRIVATE PLACEMENT
Rhea-AI Summary
BioVaxys Technology Corp. completes the first tranche of a non-brokered private placement, raising $1,103,500 through the issuance of 36,783,334 Units at $0.03 per Unit. Each Unit includes one Common Share and one Warrant. The Company plans to use the net proceeds for working capital and anticipates closing the second tranche by February 9th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.11%
Tags
none
Stock BVAXF logo
BioVaxys Technology Corp

OTC:BVAXF

BVAXF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BVAXF Stock Data

8.49M
125.30M
6.61%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Canada
Etobicoke